Orexin/hypocretin system and autonomic control :New insights and clinical correlations

Neurology

Volumn 82, Issue 3, 2014, Pages 271-278

  Grimaldi, Daniela ^a,b   Silvani, Alessandro ^a   Benarroch, Eduardo E ^c   Cortelli, Pietro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF CHICAGO   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN B; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

AROUSAL; ARTERIAL PRESSURE; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; BODY MASS; BODY WEIGHT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR REFLEX; CARDIOVASCULAR RESPONSE; CATAPLEXY; CIRCADIAN RHYTHM; DISEASE PREDISPOSITION; ENERGY; ENERGY METABOLISM; FEEDING; GASTROINTESTINAL TRACT FUNCTION; HOMEOSTASIS; HUMAN; MORBIDITY; NARCOLEPSY; NEUROENDOCRINE SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEUS RAPHE PALLIDUS; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY FUNCTION; SLEEP; SYMPATHETIC FUNCTION; THERMOREGULATION; WAKEFULNESS; ANIMAL; AUTONOMIC NERVOUS SYSTEM; BRAIN; DEFICIENCY; METABOLISM; NERVE TRACT; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; BRAIN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEURAL PATHWAYS; NEUROPEPTIDES; SIGNAL TRANSDUCTION;

EID: 84895761507     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000045     Document Type: Article

References (81)

1. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95:322-327.
2. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-585.
3. Gotter AL,Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology: LXXXVI: Orexin receptor function, nomenclature and pharmacology. Pharmacol Rev 2012;64:389-420.
4. Kukkonen JP. Physiology of the orexinergic/hypocretinergic system: A revisit in 2012. Am J Physiol Cell Physiol 2013; 304:C2-C32.
5. Sakurai T. The neural circuit of orexin (hypocretin): Maintaining sleep and wakefulness. Nat Rev Neurosci 2007;8:171-181.
6. Sakurai T, Mieda M. Connectomics of orexin-producing neurons: Interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol Sci 2011;32:451-462.
7. Harris GC, Aston-Jones G. Arousal and reward: A dichotomy in orexin function. Trends Neurosci 2006;29:571-577.
8. Sakurai T, Nagata R, Yamanaka A, et al. Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in mice. Neuron 2005;46:297-308.
9. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18:9996-10015.
10. Lazarenko RM, Stornetta RL, Bayliss DA, Guyenet PG. Orexin A activates retrotrapezoid neurons in mice. Respir Physiol Neurobiol 2011;175:283-287.
11. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001;435:6-25.
12. España RA, Scammell TE. Sleep neurobiology from a clinical perspective. Sleep 2011;34:845-858.
13. Eriksson KS, Sergeeva OA, Selbach O, Haas HL. Orexin (hypocretin)/ dynorphin neurons control GABAergic inputs to tuberomammillary neurons. Eur J Neurosci 2004;19: 1278-1284.
14. Schöne C, Cao ZF, Apergis-Schoute J, Adamantidis A, Sakurai T, Burdakov D. Optogenetic probing of fast glutamatergic transmission from hypocretin/orexin to histamine neurons in situ. J Neurosci 2012;32:12437-12443.
15. Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007;450: 420-424.
16. Sasaki K, Suzuki M, Mieda M, Tsujino N, Roth B, Sakurai T. Pharmacogenetic modulation of orexin neurons alters sleep/wakefulness states in mice. PLoS One 2011;6: E20360.
17. Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 2005;25:6716-6720.
18. Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 2005;46:787-798.
19. Takahashi K, Lin JS, Sakai K. Neuronal activity of orexin and non-orexin waking-active neurons during wake-sleep states in the mouse. Neuroscience 2008;153:860-870.
20. Yoshida Y, Fujiki N, Nakajima T, et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 2001;14:1075-1081.
21. Kiyashchenko LI, Mileykovskiy BY, Maidment N, et al. Release of hypocretin (orexin) during waking and sleep states. J Neurosci 2002;22:5282-5286.
22. Ciriello J, de Oliveira CV. Cardiac effects of hypocretin-1 in nucleus ambiguus. Am J Physiol 2003;284:R1611-R1620.
23. Krowicki ZK, Burmeister MA, Berthoud HR, Scullion RT, Fuchs K, Hornby PJ. Orexins in rat dorsal motor nucleus of the vagus potently stimulate gastric motor function. Am J Physiol Gastrointest Liver Physiol 2002;283:G465-G472.
24. Dampney RA. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev 1994;74: 323-364.
25. Shirasaka T, Nakazato M, Matsukura S, Takasaki M, Kannan H. Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol 1999;277:R1780-R1785.
26. Shahid IZ, Rahman AA, Pilowsky PM. Orexin A in rat rostral ventrolateral medulla is pressor, sympathoexcitatory, increases barosensitivity and attenuates the somatosympathetic reflex. Br J Pharmacol 2012;165:2292-2303.
27. Iigaya K, Horiuchi J, McDowall LM, et al. Blockade of orexin receptors with Almorexant reduces cardiorespiratory responses evoked from the hypothalamus but not baro-or chemoreceptor reflex responses. Am J Physiol 2012;303:R1011-1022.
28. Furlong TM, Vianna DM, Liu L, Carrive P. Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. Eur J Neurosci 2009;30:1603-1614.
29. Li A, Hindmarch CC, Nattie EE, Paton JF. Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats. J Physiol Epub 2013 Jun 24.
30. Bastianini S, Silvani A, Berteotti C, et al. Sleep related changes in blood pressure in hypocretin-deficient narcoleptic mice. Sleep 2011;34:213-218.
31. Lo Martire V, Silvani A, Bastianini S, Berteotti C, Zoccoli G. Effects of ambient temperature on sleep and cardiovascular regulation in mice: The role of hypocretin/orexin neurons. PLoS One 2012;7:e47032.
32. Silvani A, Bastianini S, Berteotti C, et al. Sleep and cardiovascular phenotype in middle-aged hypocretin-deficient narcoleptic mice. J Sleep Res Epub 2013 Aug 29.
33. Lee YH, Dai YW, Huang SC, Li TL, Hwang LL. Blockade of central orexin 2 receptors reduces arterial pressure in spontaneously hypertensive rats. Exp Physiol 2013;98:1145-1155.
34. Kayaba Y, Nakamura A, Kasuya Y, et al. Attenuated defense response and low basal blood pressure in orexin knockout mice. Am J Physiol 2003;285:R581-R593.
35. Zhang W, Sakurai T, Fukuda Y, Kuwaki T. Orexin neuron-mediated skeletal muscle vasodilation and shift of baroreflex during defense response in mice. Am J Physiol 2006;290:R1654-R1663.
36. Dergacheva O, Philbin K, Bateman R, Mendelowitz D. Hypocretin-1 (orexin A) prevents the effects of hypoxia/hypercapnia and enhances the GABAergic pathway from the lateral paragigantocellular nucleus to cardiac vagal neurons in the nucleus ambiguus. Neuroscience 2011;175:18-23.
37. Schwimmer H, Stauss HM, Abboud FM, Nishino S, Mignot E, Zeitzer JM. Effects of sleep on the cardiovascular and thermoregulatory systems: A possible role for hypocretins. J Appl Physiol 2010;109:1053-1063.
38. Silvani A, Bastianini S, Berteotti C, Lo Martire V, Zoccoli G. Control of cardiovascular variability during undisturbed wake-sleep behavior in hypocretin-deficient mice. Am J Physiol Regul 2012;302:R958-964.
39. Silvani A. Physiological sleep-dependent changes in arterial blood pressure: Central autonomic commands and baroreflex control. Clin Exp Pharmacol Physiol 2008;35:987-994.
40. Hermida RC, Ayala DE, Mojon A, Fernandez. Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level: The "normotensive non-dipper" paradox. Chronobiol Int 2013;30:87-98.
41. Lubkin M, Stricker-Krongrad A. Independent feeding and metabolic actions of orexins in mice. Biochem Biophys Res Commun 1998;253:241-245.
42. Tupone D, Madden CJ, Cano G, Morrison SF. An orexinergic projection from perifornical hypothalamus to raphe pallidus increases rat brown adipose tissue thermogenesis. J Neurosci 2011;31:15944-15955.
43. Luong L, Carrive P. Orexin microinjection in the medullary raphe increases heart rate and arterial pressure but does not reduce tail skin blood flow in the awake rat. Neuroscience 2012;202:209-217.
44. Mochizuki T, Klerman EB, Sakurai T, Scammell TE. Elevated body temperature during sleep in orexin knockout mice. Am J Physiol 2006;291:R533-R540.
45. Zhang W, Sunanaga J, Takahashi Y, et al. Orexin neurons are indispensable for stress-induced thermogenesis in mice. J Physiol 2010;588:4117-4129.
46. Zhang S, Zeitzer JM, Sakurai T, Nishino S, Mignot E. Sleep/wake fragmentation disrupts metabolism in a mouse model of narcolepsy. J Physiol 2007;581:649-663.
47. Takahashi N, Okumura T, Yamada H, Kohgo Y. Stimulation of gastric acid secretion by centrally administered orexin-A in conscious rats. Biochem Biophys Res Commun 1999;254:623-627.
48. Miyasaka K, Masuda M, Kanai S, Sato N, Kurosawa M, Funakoshi A. Central Orexin-A stimulates pancreatic exocrine secretion via the vagus. Pancreas 2002;25:400-404.
49. Kobashi M, Furudono Y, Matsuo R, Yamamoto T. Central orexin facilitates gastric relaxation and contractility in rats. Neurosci Lett 2002;332:171-174.
50. Nozu T, Kumei S, Takakusaki K, Ataka K, Fujimiya M, Okumura T. Central orexin-A increases colonic motility in conscious rats. Neurosci Lett 2011;498:143-146.
51. Williams RH, Jensen LT, Verkhratsky A, Fugger L, Burdakov D. Control of hypothalamic orexin neurons by acid and CO2. Proc Natl Acad Sci USA 2007;104: 10685-10690.
52. Nakamura A, Zhang W, Yanagisawa M, Fukuda Y, Kuwaki T. Vigilance state-dependent attenuation of hypercapnic chemoreflex and exaggerated sleep apnea in orexin knockout mice. J Appl Physiol 2007;102:241-248.
53. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-997.
54. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-474.
55. Dauvilliers Y, Arnulf I,Mignot E. Narcolepsy with cataplexy. Lancet 2007;369:499-511.
56. Yoss RE, Moyer NJ, Ogle KN. The pupillogram and narcolepsy: A method to measure decreased levels of wakefulness. Neurology 1969;19:921-928.
57. Karacan I. Erectile dysfunction in narcoleptic patients. Sleep 1986;9:227-231.
58. Plazzi G, Moghadam KK, Maggi LS, et al. Autonomic disturbances in narcolepsy. Sleep Med Rev 2011;15: 187-196.
59. Grimaldi D, Calandra-Buonaura G, Provini F, et al. Abnormal sleep-cardiovascular system interaction in narcolepsy with cataplexy: Effects of hypocretin deficiency in humans. Sleep 2012;35:519-528.
60. Dauvilliers Y, Jaussent I, Krams B, et al. Non-dipping blood pressure profile in narcolepsy with cataplexy. PLoS One 2012;7:e38977.
61. Silvani A, Grimaldi D, Barletta G, et al. Cardiovascular variability as a function of sleep-wake behaviour in narcolepsy with cataplexy. J Sleep Res 2013;22:178-184.
62. Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: A comparison with the general population. Sleep Med 2013;14:488-492.
63. Sachs C, Kaijser L. Autonomic regulation of cardiopulmonary functions in sleep apnea syndrome and narcolepsy. Sleep 1982;5:227-238.
64. Fronczek R, Overeem S, Reijntjes R, Lammers GJ, van Dijk JG, Pijl H. Increased heart rate variability but normal resting metabolic rate in hypocretin/orexin-deficient human narcolepsy. J Clin Sleep Med 2008;4:248-254.
65. Grimaldi D, Pierangeli G, Barletta G, et al. Spectral analysis of heart rate variability reveals an enhanced sympathetic activity in narcolepsy with cataplexy. Clin Neurophysiol 2010;121:1142-1147.
66. Hublin C, Matikainen E, Partinen M. Autonomic nervous system function in narcolepsy. J Sleep Res 1994;3:131-137.
67. Ferini-Strambi L, Spera A, Oldani A, et al. Autonomic function in narcolepsy: Power spectrum analysis of heart rate variability. J Neurol 1997;244:252-255.
68. Rubboli G, d'Orsi G, Zaniboni A, et al. A video-polygraphic analysis of the cataplectic attack. Clin Neurophysiol 2000; 111(suppl 2):S120-S128.
69. Donadio V, Plazzi G, Vandi S, et al. Sympathetic and cardiovascular activity during cataplexy in narcolepsy. J Sleep Res 2008;17:458-463.
70. Czeisler CA, Zimmerman JC, Ronda JM, Moore-Ede MC, Weitzman ED. Timing of REM sleep is coupled to the circadian rhythm of body temperature in man. Sleep 1980;2: 329-346.
71. Mosko SS, Holowach JB, Sassin JF. The 24-hour rhythm of core temperature in narcolepsy. Sleep 1983;6:137-146.
72. Mayer G,Hellmann F, Leonhard E,Meier-Ewert K. Circadian temperature and activity rhythms in unmedicated narcoleptic patients. Pharmacol Biochem Behav 1997;58:395-402.
73. Pollak CP, Wagner DR. Core body temperature in narcoleptic and normal subjects living in temporal isolation. Pharmacol Biochem Behav 1994;47:65-71.
74. Grimaldi D, Agati P, Pierangeli G, et al. Hypocretin deficiency in narcolepsy with cataplexy is associated with a normal body core temperature modulation. Chronobiol Int 2010;27:1596-1608.
75. Fronczek R, Overeem S, Lammers GJ, van Dijk JG, Van Someren EJ. Altered skin-temperature regulation in narcolepsy relates to sleep propensity. Sleep 2006; 29:1444-1449.
76. Fronczek R, Raymann RJ, Overeem S, et al. Manipulation of skin temperature improves nocturnal sleep in narcolepsy. J Neurol Neurosurg Psychiatry 2008;79:1354-1357.
77. Honda Y, Doi Y, Ninomiya R, Ninomiya C. Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep 1986;9:254-259.
78. Schuld A, Hebebrand J, Geller F, Pollmächer T. Increased body-mass index in patients with narcolepsy. Lancet 2000; 355:1274-1275.
79. Heier MS, Jansson TS, Gautvik KM. Cerebrospinal fluid hypocretin 1 deficiency, overweight, and metabolic dysregulation in patients with narcolepsy. J Clin Sleep Med 2011;7: 653-658.
80. Poli F, Plazzi G, Di Dalmazi G, et al. Body mass indexindependent metabolic alterations in narcolepsy with cataplexy. Sleep 2009;32:1491-1497.
81. Beitinger PA, Fulda S, Dalal MA, et al. Glucose tolerance in patients with narcolepsy. Sleep 2012;35:231-236.